170 related articles for article (PubMed ID: 35812375)
1. Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary.
Mei J; Wang H; Fan H; Ding J; Xu J
Front Immunol; 2022; 13():900119. PubMed ID: 35812375
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.
Sheng J; Pan H; Han W
Front Immunol; 2023; 14():1181444. PubMed ID: 37153561
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass: A case report.
Zhang M; Zhao M; Jin LF; Shen WZ
Medicine (Baltimore); 2021 Dec; 100(48):e28074. PubMed ID: 35049231
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.
Kamada T; Ishiguro H; Okada S; Takeuchi H; Takahashi J; Nakashima K; Nakaseko Y; Suzuki N; Ohdaira H; Suzuki Y
Ann Med Surg (Lond); 2020 Dec; 60():31-35. PubMed ID: 33101670
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.
Egger EK; Ralser DJ; Lindner K; Recker F; Marinova M; Savchenko O; Lau JF; Mustea A
Front Immunol; 2021; 12():686879. PubMed ID: 34367146
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immune profiling for cancer of unknown primary site.
Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
[TBL] [Abstract][Full Text] [Related]
8. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
11. Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review.
Tan S; Yu J; Huang Q; Zhou N; Xiong X; Gou H
Front Pharmacol; 2022; 13():1037646. PubMed ID: 36518664
[No Abstract] [Full Text] [Related]
12. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
13. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
15. Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
Harada G; Amano MT; Antonacio FF; Behar MH; Nabuco-de-Araujo PHX; Buchpiguel CA; Junior GC
Clin Lung Cancer; 2021 Sep; 22(5):e708-e711. PubMed ID: 33658161
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
[TBL] [Abstract][Full Text] [Related]
18. 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report.
Zhao W; Zhao N; Zhang M; Li Z; Wang N; Shen W; Dong Y; Nie Y; Li Z
Front Oncol; 2023; 13():1242460. PubMed ID: 37886174
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract][Full Text] [Related]
20. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait.
Huey RW; Smaglo BG; Estrella JS; Matamoros A; Overman MJ; Varadhachary GR; Raghav KPS
Oncologist; 2021 Apr; 26(4):e650-e657. PubMed ID: 33524217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
